NATALEE: Phase III study of ribociclib (RIBO) plus endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).

被引：43

作者：

Slamon, Dennis J.

Fasching, Peter A.

Patel, Ravindranath

Verma, Sunil

Hurvitz, Sara A.

Chia, Stephen K. L.

Crown, John

Martin, Miguel

Barrios, Carlos H.

Spera, Gonzalo

Lopez, Celine

Hor, Ines

Pelov, Diana

Hughes, Gareth

Nawinne, Moditha

Hortobagyi, Gabriel N.

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[2] Univ Hosp Erlangen, Erlangen, Germany

[3] Comprehens Blood & Canc Ctr, Bakersfield, CA USA

[4] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada

[5] BC Canc Agcy, Vancouver, BC, Canada

[6] St Vincents Univ Hosp, Dept Med Oncol, Dublin, Ireland

[7] Hosp Gen Univ Gregorio Maranon, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain

[8] Latin Amer Cooperat Oncol Grp, Porto Alegre, RS, Brazil

[9] Translat Res Oncol, Montevideo, Uruguay

[10] Translat Res Oncol TRIO, Paris, France

[11] Novartis Pharmaceut, E Hanover, NJ USA

[12] Novartis Pharma AG, Basel, Switzerland

[13] Novartis Pharma AG, Basil, Switzerland

[14] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.TPS597

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS597

引用

页数：2

共 50 条

[1] EarLEE-2: A phase 3 study of ribociclib plus endocrine therapy (ET) for adjuvant treatment of patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), intermediate-risk, early breast cancer (EBC)
O'Shaughnessy, Joyce
Alba, Emilio
Bardia, Aditya
Dent, Susan
Dieras, Veronique
Hortobagyi, Gabriel
Im, Seock-Ah
Montemurro, Filippo
Untch, Michael
Yardley, Denise A.
Chakravartty, Arunava
Germa, Caroline
Miller, Michelle
Slamon, Dennis
CANCER RESEARCH, 2018, 78 (04)
[2] EarLEE-1: A phase 3 study of ribociclib plus endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-), high-risk, early breast cancer (EBC)
Martin Jimenez, M.
Bachelot, T.
Barrios, C.
Blackwell, K.
Chia, S.
De Laurentiis, M.
Hurvitz, S.
Janni, W.
Kaufman, B.
Loi, S.
Schmid, P.
Slamon, D.
Hazell, K.
Mondal, S.
Shilkrut, M.
Germa, C.
Hortobagyi, G.
ANNALS OF ONCOLOGY, 2017, 28
[3] RIBOCICLIB AND ENDOCRINE THERAPY (ET) IN HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER-2) BREAST CANCER: THE MONALEESA CLINICAL TRIALS PROGRAM
Campone, Mario
Tripathy, Debu
Chia, Stephen
Diaz-Padilla, Ivan
Lorenc, Karen R.
Miller, Michelle
Germa, Caroline
Conte, Pierfranco
BREAST, 2017, 36 : S50 - S50
[4] Ribociclib plus endocrine therapy (ET) doublet combinations in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Phase I clinical activity and impact of molecular alterations
Julie, Dejan
Campone, Mario
Munster, Pamela
Ismail-Khan, Roohi
Estevez, Laura Garcia
Chavez-MacGregor, Mariana
Frassoldati, Antonio
Hui, Rina
Mayer, Ingrid A.
Cortes, Javier
Goncalves, Anthony
De Boer, Richard H.
Dirix, Luc
Tolaney, Sara M.
Lee, Soo Chin
Maur, Michela
Wang, Yingbo
Su, Faye
Dobson, Jason R.
Germa, Caroline
Hewes, Becker
Bardia, Aditya
CANCER RESEARCH, 2017, 77
[5] CompLEEment-1: Phase 3b study of ribociclib plus letrozole for the treatment of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC
De Laurentiis, M.
Martin Jimenez, M.
Ring, A.
Cottu, P.
Zhou, K.
Wu, J.
Zarate, J. P.
Zamagni, C.
ANNALS OF ONCOLOGY, 2017, 28
[6] ECONOMIC ANALYSIS OF COMBINATION THERAPY WITH ALPELISIB AND FULVESTRANT FOR TREATMENT OF HORMONE RECEPTOR-POSITIVE (HR plus ) AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER
Delevry, D.
Le, Q. A.
VALUE IN HEALTH, 2020, 23 : S32 - S33
[7] BUDGET IMPACT OF RIBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER IN DENMARK
Moller, A. H.
Oddershede, L.
VALUE IN HEALTH, 2019, 22 : S483 - S483
[8] Ribociclib plus letrozole for first-line treatment of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers
Andre, Fabrice
Stemmer, Salomon M.
Campone, Mario
Petrakova, Katarina
Paluch-Shimon, Shani
Yap, Yoon-Sim
Marschner, Norbert
Chan, Arlene
Villanueva, Cristian
Hart, Lowell L.
Arteaga, Carlos L.
Sonke, Gabe S.
Grischke, Eva-Maria
Alba, Emilio
Nusch, Arnd
Yardley, Denise A.
Jakobsen, Erik
Blau, Sibel
Tolaney, Sara M.
Su, Faye
He, Wei
Germa, Caroline
Hortobagyi, Gabriel N.
CANCER RESEARCH, 2017, 77
[9] The role of ribociclib in hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer: the EarLEE adjuvant clinical trials program
De laurentiis, M.
Montemurro, F.
Bachelot, T.
Martin, M.
Barrios, C.
Kaufman, B.
Schmid, P.
Alba, E.
Dieras, V.
Mondal, S.
Chakravartty, A.
Shilkrut, M.
Miller, M.
Untch, M.
ANNALS OF ONCOLOGY, 2017, 28
[10] Hormone receptor positive (HR plus )/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer: Sequencing of chemotherapy and endocrine therapy
Engel-Nitz, Nicole M.
Hao, Yanni
Rogerio, Jaqueline Willemann
Turnbull, James D.
Rey, Gabriel Gomez
Sullivan, Jane
Rossof, Arthur H.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26)

← 1 2 3 4 5 →